Publications

BibTex format

@article{Schmidt:2020:10.1002/ijc.32314,
author = {Schmidt, JA and Fensom, GK and Rinaldi, S and Scalbert, A and Appleby, PN and Achaintre, D and Gicquiau, A and Gunter, MJ and Ferrari, P and Kaaks, R and Kühn, T and Boeing, H and Trichopoulou, A and Karakatsani, A and Peppa, E and Palli, D and Sieri, S and Tumino, R and Bueno-de-Mesquita, B and Agudo, A and Sánchez, M-J and Chirlaque, M-D and Ardanaz, E and Larrañaga, N and Perez-Cornago, A and Assi, N and Riboli, E and Tsilidis, KK and Key, TJ and Travis, RC},
doi = {10.1002/ijc.32314},
journal = {International Journal of Cancer},
pages = {720--730},
title = {Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: A prospective study of 3,057 matched case-control sets from EPIC},
url = {http://dx.doi.org/10.1002/ijc.32314},
volume = {146},
year = {2020}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Metabolomics may reveal novel insights into the etiology of prostate cancer, for which few risk factors are established. We investigated the association between patterns in baseline plasma metabolite profile and subsequent prostate cancer risk, using data from 3,057 matched case-control sets from the European Prospective Investigation into Cancer and Nutrition (EPIC). We measured 119 metabolite concentrations in plasma samples, collected on average 9.4 years before diagnosis, by mass spectrometry (AbsoluteIDQ p180 Kit, Biocrates Life Sciences AG). Metabolite patterns were identified using treelet transform, a statistical method for identification of groups of correlated metabolites. Associations of metabolite patterns with prostate cancer risk (OR1SD ) were estimated by conditional logistic regression. Supplementary analyses were conducted for metabolite patterns derived using principal component analysis and for individual metabolites. Men with metabolite profiles characterized by higher concentrations of either phosphatidylcholines or hydroxysphingomyelins (OR1SD  = 0.77, 95% confidence interval 0.66-0.89), acylcarnitines C18:1 and C18:2, glutamate, ornithine and taurine (OR1SD  = 0.72, 0.57-0.90), or lysophosphatidylcholines (OR1SD  = 0.81, 0.69-0.95) had lower risk of advanced stage prostate cancer at diagnosis, with no evidence of heterogeneity by follow-up time. Similar associations were observed for the two former patterns with aggressive disease risk (the more aggressive subset of advanced stage), while the latter pattern was inversely related to risk of prostate cancer death (OR1SD  = 0.77, 0.61-0.96). No associations were observed for prostate cancer overall or less aggressive tumor subtypes. In conclusion, metabolite patterns may be related to lower risk of more aggressive prostate tumors and prostate cancer death, and might be relevant to etiology of advanced stage prostate cancer.
AU  - Schmidt,JA
AU  - Fensom,GK
AU  - Rinaldi,S
AU  - Scalbert,A
AU  - Appleby,PN
AU  - Achaintre,D
AU  - Gicquiau,A
AU  - Gunter,MJ
AU  - Ferrari,P
AU  - Kaaks,R
AU  - Kühn,T
AU  - Boeing,H
AU  - Trichopoulou,A
AU  - Karakatsani,A
AU  - Peppa,E
AU  - Palli,D
AU  - Sieri,S
AU  - Tumino,R
AU  - Bueno-de-Mesquita,B
AU  - Agudo,A
AU  - Sánchez,M-J
AU  - Chirlaque,M-D
AU  - Ardanaz,E
AU  - Larrañaga,N
AU  - Perez-Cornago,A
AU  - Assi,N
AU  - Riboli,E
AU  - Tsilidis,KK
AU  - Key,TJ
AU  - Travis,RC
DO  - 10.1002/ijc.32314
EP  - 730
PY  - 2020///
SN  - 0020-7136
SP  - 720
TI  - Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: A prospective study of 3,057 matched case-control sets from EPIC
T2  - International Journal of Cancer
UR  - http://dx.doi.org/10.1002/ijc.32314
UR  - https://www.ncbi.nlm.nih.gov/pubmed/30951192
UR  - http://hdl.handle.net/10044/1/69608
VL  - 146
ER  -

Download

ProfessorElioRiboli

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)